Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors and Body Mass Index in Patients on Long Term Treatment: A Cross-Sectional Comparative Study
International Journal of Drug Delivery Technology · 06.04.2026 · 16 (2)
DOI: 10.25258/ijddt.16.2.39 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 06.04.2026. Verfasst von Shreya Hegde und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) are the most commonly prescribed antidepressants but changes in body weight (BW) is a concern with the chronic use of antidepressant. We observed the effect of SSRIs and SNRIs on BW and body mass index (BMI) in patients on long-term therapy while avoiding the other confounding factors.
Objectives
To assess and compare the changes in BW and BMI in patients on monotherapy with either SSRIs (escitalopram, sertraline or fluoxetine) or SNRIs (duloxetine, venlafaxine or desvenlafaxine).
Methods
In a cross-sectional, hospital-based, comparative study, the patients on monotherapy with- sertraline, fluoxetine, escitalopram, venlafaxine, desvenlafaxine or duloxetine for a period of ≥ 24 weeks were evaluated for the changes in their BW and BMI. In patients showing a change in weight, causality assessment was done by Naranjo’s algorithm and severity assessment by modified Hartwig and Siegel scale. Results and Conclusion: Fifty-eight patients were included (SSRIs = 30; SNRIs = 28). Escitalopram and sertraline were associated with increases in BW and BMI, whereas fluoxetine, duloxetine, venlafaxine, and desvenlafaxine showed reductions. Median weight gain with escitalopram and sertraline was 2.0 kg (IQR 1.5) and 2.0 kg (IQR 1.0), respectively. Fluoxetine showed mean reductions of 1.20 ± 1.32 kg in BW and 0.44 ± 0.50 kg/m² in BMI. Statistically significant changes were observed with SSRIs but not with SNRIs. Between-group analysis demonstrated significantly greater weight gain with SSRIs compared with weight reduction with SNRIs (p < 0.001). All changes were classified as probable and mild. As weight changes remained
Zitieren
APA
Hegde, S., Udaykumar, P., & Yadiyal, A. (2026). Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors and Body Mass Index in Patients on Long Term Treatment: A Cross-Sectional Comparative Study. International Journal of Drug Delivery Technology, 16(2). https://doi.org/10.25258/ijddt.16.2.39
Vancouver
Hegde S, Udaykumar P, Yadiyal A. Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors and Body Mass Index in Patients on Long Term Treatment: A Cross-Sectional Comparative Study. International Journal of Drug Delivery Technology. 2026;16(2). doi:10.25258/ijddt.16.2.39
BibTeX
@article{Hegde2026,
author = {Hegde, Shreya and Udaykumar, Padmaja and Yadiyal, Aruna},
title = {Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors and Body Mass Index in Patients on Long Term Treatment: A Cross-Sectional Comparative Study},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {2},
doi = {10.25258/ijddt.16.2.39}
}
EUVIMED